136 related articles for article (PubMed ID: 35635145)
21. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
[TBL] [Abstract][Full Text] [Related]
22. Dual Allosteric Inhibition of SHP2 Phosphatase.
Fodor M; Price E; Wang P; Lu H; Argintaru A; Chen Z; Glick M; Hao HX; Kato M; Koenig R; LaRochelle JR; Liu G; McNeill E; Majumdar D; Nishiguchi GA; Perez LB; Paris G; Quinn CM; Ramsey T; Sendzik M; Shultz MD; Williams SL; Stams T; Blacklow SC; Acker MG; LaMarche MJ
ACS Chem Biol; 2018 Mar; 13(3):647-656. PubMed ID: 29304282
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, biological evaluation, common feature pharmacophore model and molecular dynamics simulation studies of ethyl 4-(phenoxymethyl)-2-phenylthiazole-5-carboxylate as Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
Wu J; Li W; Zheng Z; Lu X; Zhang H; Ma Y; Wang R
J Biomol Struct Dyn; 2021 Mar; 39(4):1174-1188. PubMed ID: 32036779
[TBL] [Abstract][Full Text] [Related]
24. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
25. Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2.
Chio CM; Lim CS; Bishop AC
Biochemistry; 2015 Jan; 54(2):497-504. PubMed ID: 25519989
[TBL] [Abstract][Full Text] [Related]
26. Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors.
Franciosa G; Olsen JV
Oncotarget; 2023 Mar; 14():281-283. PubMed ID: 36999992
[No Abstract] [Full Text] [Related]
27. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.
Tang K; Jia YN; Yu B; Liu HM
Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411
[TBL] [Abstract][Full Text] [Related]
28. Identification of demethylincisterol A
Chen C; Liang F; Chen B; Sun Z; Xue T; Yang R; Luo D
Eur J Pharmacol; 2017 Jan; 795():124-133. PubMed ID: 27939989
[TBL] [Abstract][Full Text] [Related]
29. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
[TBL] [Abstract][Full Text] [Related]
30. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
Romero C; Lambert LJ; Sheffler DJ; De Backer LJS; Raveendra-Panickar D; Celeridad M; Grotegut S; Rodiles S; Holleran J; Sergienko E; Pasquale EB; Cosford NDP; Tautz L
J Biol Chem; 2020 Feb; 295(9):2601-2613. PubMed ID: 31953320
[TBL] [Abstract][Full Text] [Related]
31. Small-Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview.
Mitra R; Ayyannan SR
ChemMedChem; 2021 Mar; 16(5):777-787. PubMed ID: 33210828
[TBL] [Abstract][Full Text] [Related]
32. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells.
Raveendra-Panickar D; Finlay D; Layng FI; Lambert LJ; Celeridad M; Zhao M; Barbosa K; De Backer LJS; Kwong E; Gosalia P; Rodiles S; Holleran J; Ardecky R; Grotegut S; Olson S; Hutchinson JH; Pasquale EB; Vuori K; Deshpande AJ; Cosford NDP; Tautz L
J Biol Chem; 2022 Jan; 298(1):101477. PubMed ID: 34896393
[TBL] [Abstract][Full Text] [Related]
33. Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2.
LaRochelle JR; Fodor M; Ellegast JM; Liu X; Vemulapalli V; Mohseni M; Stams T; Buhrlage SJ; Stegmaier K; LaMarche MJ; Acker MG; Blacklow SC
Bioorg Med Chem; 2017 Dec; 25(24):6479-6485. PubMed ID: 29089257
[TBL] [Abstract][Full Text] [Related]
34. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
35. Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020).
Wu J; Zhang H; Zhao G; Wang R
Curr Med Chem; 2021; 28(19):3825-3842. PubMed ID: 32988341
[TBL] [Abstract][Full Text] [Related]
36. Toward a Treatment of Cancer: Design and In Vitro/In Vivo Evaluation of Uncharged Pyrazoline Derivatives as a Series of Novel SHP2 Inhibitors.
Dai J; Zhang Y; Gao Y; Bai X; Liu F; Li S; Yu Y; Hu W; Shi T; Shi D; Li X
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408869
[TBL] [Abstract][Full Text] [Related]
37. A procedure combining molecular docking and semiempirical method PM7 for identification of selective Shp2 inhibitors.
Rocha SFLS; Sant'Anna CMR
Biopolymers; 2019 Nov; 110(11):e23320. PubMed ID: 31268558
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of SHP2 as an approach to block RAS-driven cancers.
Chou YT; Bivona TG
Adv Cancer Res; 2022; 153():205-236. PubMed ID: 35101231
[TBL] [Abstract][Full Text] [Related]
39. Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2
Zhou L; Feng Y; Ma YC; Zhang Z; Wu JW; Du S; Li WY; Lu XH; Ma Y; Wang RL
J Mol Graph Model; 2021 Mar; 103():107807. PubMed ID: 33338846
[TBL] [Abstract][Full Text] [Related]
40. Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2
Du S; Lu XH; Li WY; Li LP; Ma YC; Zhou L; Wu JW; Ma Y; Wang RL
Mol Divers; 2021 Aug; 25(3):1873-1887. PubMed ID: 33392964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
